Caution, this is an AI generated summary based on literature. This may have errors, see here for more.
Please share your feedback with us.
hsa-miR-3202: Hsa-mir-3202 is a microRNA that has been studied in various contexts [PMC9869167]. It has been found to inhibit the proliferation of vascular smooth muscle cells (VSMCs) by suppressing the expression of SLC7A5 [PMC8528547]. It has also been implicated in the regulation of genes involved in thoracic aortic dissection (TAD) [PMC8528547]. Dysregulation of hsa-mir-3202 has been observed in mild traumatic brain disorders and headache attacks [PMC9438144]. In addition, hsa-mir-3202 has been identified as one of the top differentially expressed miRNAs in chronic thromboembolic pulmonary hypertension (CTEPH) and endometrial receptivity [PMC8075669] [PMC6097487]. It is also involved in the regulation of genes related to histamine N-methyltransferase (HNMT) and osteoporosis [PMC9678002] [PMC7543140]. Furthermore, hsa-mir-3202 has been predicted to target TSEN54 and bind to the ORF1a/b region of the SARS-CoV-2 genome [PMC10120902] [PMC9346380]. The ceRNA hypothesis suggests that hsa-mir-3202 can be competitively bound by lncRNAs ARHGAP22-IT1 and SNHG8, leading to upregulation of SLC7A5 and promotion of VSMC proliferation and TAD development [PMC8528547]. Overall, hsa-mir-3202 plays a role in various biological processes and may have diagnostic and therapeutic potential in different diseases.
Genome locations
Gene Ontology annotations
Ancestor Chart
Loading ontology ancestors...
Failed to load QuickGO Ancestor chart
Sequence
Sequence features are shown above as colored rectangles.
Zoom in and click to view details, or
Reset